药物与滥用药物对常规实践中[123I]I-FP-CIT SPECT多巴胺转运体显像潜在影响的系统综述
该研究系统检索2008年1月至2022年11月文献,评估药物及滥用药物(含烟草和酒精)对人体纹状体多巴胺转运体结合的可能影响,共纳入44项临床研究,更新了可能影响[123I]I-FP-CIT SPECT视觉判读的药物清单。作者期望在显像前及时停用这些药物可减少假阳性报告,但停药决定须由负责患者的专科医生权衡利弊后作出。
要点
- 系统综述纳入44项临床研究,更新了可能影响纹状体[123I]I-FP-CIT结合的药物与滥用药物清单。
- 作者期望显像前及时停用这些药物可减少假阳性报告,但停药须由专科医生权衡利弊决定。
- 该综述为2008年原综述的更新,检索2008年1月至2022年11月文献且无语言限制。
核心结论
- 作者期望在DAT显像前及时停用可能影响纹状体[123I]I-FP-CIT结合的药物和滥用药物可减少假阳性报告的发生率。
- 是否停用任何药物必须由负责患者诊疗的专科医生在权衡停药利弊后作出决定。
研究设计与样本
- 系统综述,检索2008年1月至2022年11月的文献且无语言限制,评估药物和滥用药物(包括烟草和酒精使用)对人体纹状体DAT结合的可能影响。
- 系统文献检索共识别838篇唯一出版物,最终纳入44项临床研究。
主要发现
- 基于纳入的44项临床研究,作者找到了支持原推荐的新证据,并获得其他药物对纹状体DAT结合潜在影响的新发现。
- 据此更新了在常规临床实践中可能影响[123I]I-FP-CIT SPECT扫描视觉判读的药物和滥用药物清单。
临床怎么用
- 在常规实践中,DAT显像常用于支持帕金森病或路易体痴呆的诊断。
- 作者期望显像前及时停用可能影响纹状体DAT结合的药物和滥用药物以减少假阳性报告,但停药决定须由负责患者诊疗的专科医生权衡利弊后作出。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In routine practice, dopamine transporter (DAT) imaging is frequently used as a diagnostic tool to support the diagnosis of Parkinson's disease or dementia with Lewy bodies. In 2008, we published a review on which medications and drugs of abuse may influence striatal [123I]I-FP-CIT binding and consequently may influence the visual read of an [123I]I-FP-CIT SPECT scan. We made recommendations on which drugs should be withdrawn before performing DAT imaging in routine practice. Here, we provide an update of the original work based on published research since 2008. METHODS: We performed a systematic review of literature without language restriction from January 2008 until November 2022 to evaluate the possible effects of medications and drugs of abuse, including the use of tobacco and alcohol, on striatal DAT binding in humans. RESULTS: The systematic literature search identified 838 unique publications, of which 44 clinical studies were selected. Using this approach, we found additional evidence to support our original recommendations as well as some new findings on potential effect of other medications on striatal DAT binding. Consequently, we updated the list of medications and drugs of abuse that may influence the visual read of [123I]I-FP-CIT SPECT scans in routine clinical practice. CONCLUSION: We expect that a timely withdrawal of these medications and drugs of abuse before DAT imaging may reduce the incidence of false-positive reporting. Nevertheless, the decision to withdraw any medication must be made by the specialist in charge of the patient's care and considering the pros and cons of doing so.
引用
- Chahid Y, Sheikh ZH, Mitropoulos M, et al. A systematic review of the potential effects of medications and drugs of abuse on dopamine transporter imaging using [123I]I-FP-CIT SPECT in routine practice. Eur J Nucl Med Mol Imaging. 2023. PMID: 36847827. doi:10.1007/s00259-023-06171-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。